https://scholars.lib.ntu.edu.tw/handle/123456789/582961
標題: | Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma | 作者: | Sahu D. CHIA-LANG HSU Lin C.-C. Yang T.-W. WEN-MING HSU Ho S.-Y. Juan H.-F. Huang H.-C. |
公開日期: | 2016 | 出版社: | Impact Journals LLC | 卷: | 7 | 期: | 36 | 起(迄)頁: | 58022-58037 | 來源出版物: | Oncotarget | 摘要: | Despite of the discovery of protein therapeutic targets and advancement in multimodal therapy, the survival chance of high-risk neuroblastoma (NB) patients is still less than 50%. MYCN amplification is a potent driver of NB, which exerts its oncogenic activity through either activating or inhibiting the transcription of target genes. Recently, long noncoding RNAs (lncRNAs) are reported to be altered in cancers including NB. However, lncRNAs that are altered by MYCN amplification and associated with outcome in high-risk NB patients are limitedly discovered. Herein, we examined the expression profiles of lncRNAs and protein-coding genes between MYCN amplified and MYCN non-amplified NB from microarray (n = 47) and RNAseq datasets (n = 493). We identified 6 lncRNAs in common that were differentially expressed (adjusted P ? 0.05 and fold change ? 2) and subsequently validated by RT-qPCR. The co-expression analysis reveals lncRNA, SNHG1 and coding gene, TAF1D highly co-expressed in NB. Kaplan-Meier analysis shows that higher expression of SNHG1 is significantly associated with poor patient survival. Importantly, multivariate analysis confirms high expression of SNHG1 as an independent prognostic marker for event-free survival (EFS) (HR = 1.58, P = 2.36E-02). In conclusion, our study unveils that SNHG1 is up-regulated by MYCN amplification and could be a potential prognostic biomarker for high-risk NB intervention. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84988418434&doi=10.18632%2foncotarget.11158&partnerID=40&md5=a19afee646aaaec3d0b6678f2585b194 https://scholars.lib.ntu.edu.tw/handle/123456789/582961 |
ISSN: | 1949-2553 | DOI: | 10.18632/oncotarget.11158 | SDG/關鍵字: | long untranslated RNA; SNHG1 RNA; transcriptome; unclassified drug; long non-coding RNA SNHG1, human; long untranslated RNA; MYCN protein, human; N Myc proto oncogene protein; TATA binding protein associated factor; tumor marker; adult; Article; cancer prognosis; cancer survival; controlled study; event free survival; female; gene; gene expression; human; human cell; major clinical study; male; neuroblastoma; reverse transcription polymerase chain reaction; RNA analysis; survival prediction; TAF1D gene; cancer staging; cohort analysis; comparative study; disease free survival; gene amplification; gene expression profiling; gene expression regulation; genetics; infant; Kaplan Meier method; metabolism; mortality; neuroblastoma; pathology; prognosis; real time polymerase chain reaction; tissue microarray; tumor cell line; upregulation; Biomarkers, Tumor; Cell Line, Tumor; Cohort Studies; Disease-Free Survival; Female; Gene Amplification; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Infant; Kaplan-Meier Estimate; Male; N-Myc Proto-Oncogene Protein; Neoplasm Staging; Neuroblastoma; Prognosis; Real-Time Polymerase Chain Reaction; RNA, Long Noncoding; TATA-Binding Protein Associated Factors; Tissue Array Analysis; Up-Regulation |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。